Q2 2025 Earnings Call Transcript August 8, 2025 Operator: Greetings, and welcome to the INmune Bio Second Quarter 2025 ...

Explore INmune Bio's Fair Values from the Community and select yours. Even when a business is losing money, it's possible for shareholders to make money if they buy a good busines ...

Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Inmune Bio ( (INMB) ) just unveiled an update.

The latest update is out from Inmune Bio ( (INMB) ).

Explore INmune Bio's Q2 2025 earnings call: new CEO, strategic shifts, XPro's Alzheimer's pause, CORDStrom advancements, and a focus on partnerships.

XPro failed to meet primary endpoints in its Phase 2 Alzheimer’s trial, but showed some positive signals in a biomarker-enriched subgroup. Cash and cash equivalents increased to $33.4 million, ...

Company to Host Conference Call Today, August 7th, at 4:30pm ETBOCA RATON, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company ...

The latest meme stock mania may have faded, but retail investors are always looking out for the next short-squeeze. Data from ...

Shares of INmune Bio climbed after the biotech company said its trial for treatment of a certain prostate cancer met its targets. The stock was up 11%, to $2.83, but is still down 65% over the ...

INmune Bio Inc. (NASDAQ:INMB) saw its stock jump 28% on Monday after announcing that its Phase I/II trial evaluating INKmune™ ...

Investing.com -- INmune Bio Inc. (NASDAQ: INMB) stock surged 28% after the company announced its Phase I/II trial of INKmune™ in metastatic castration-resistant prostate cancer (mCRPC) met both ...

Boca Raton, Florida, July 31, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company”), a clinical-stage ...